Passage Bio Inc Market Cap ($10.94 Million)
Market Cap & Net Worth: Passage Bio Inc (PASG)
Passage Bio Inc market cap. Passage Bio Inc (NASDAQ:PASG) has a market capitalization of $10.94 Million ($10.94 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26693 globally and #5570 in its home market, demonstrating a 1.22% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Passage Bio Inc's stock price $3.40 by its total outstanding shares 3217810 (3.22 Million). Also see cash efficiency ratio of Passage Bio Inc for how efficiently the company converts equity into cash flow.
Passage Bio Inc Market Cap History (2020–2026)
Passage Bio Inc market cap history from 2020 to 2026. Data shows change from $82.28 Million to $10.94 Million (-24.47% CAGR). Check Passage Bio Inc stock price for real-time trading data and today's change.
Index Memberships
Passage Bio Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #747 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2439 of 3165 |
Weight: Passage Bio Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Passage Bio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Passage Bio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore PASG net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PASG by Market Capitalization
Companies near Passage Bio Inc in the global market cap rankings as of November 4, 2026. Also see Passage Bio Inc balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Passage Bio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Passage Bio Inc (2020–2026)
Market capitalization of Passage Bio Inc from 2020 to today. Between 2020 and today, Passage Bio Inc's market cap moved from $82.28 Million to $ 10.94 Million, with a yearly change of -24.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $10.94 Million | -71.19% |
| 2025 | $37.97 Million | +1980.76% |
| 2024 | $1.82 Million | -43.85% |
| 2023 | $3.25 Million | -26.81% |
| 2022 | $4.44 Million | -78.27% |
| 2021 | $20.43 Million | -75.17% |
| 2020 | $82.28 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Passage Bio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.94 Million USD |
| MoneyControl | $10.94 Million USD |
| MarketWatch | $10.94 Million USD |
| marketcap.company | $10.94 Million USD |
| Reuters | $10.94 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Passage Bio Inc
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops P… Read more